Rivoceranib
As of the edition of 20 October 2026, Rivoceranib is a small molecule: in active development; acts on KDR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 483, 24 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Hormones; Skin and connective tissue; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Rivoceranib.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 36 | 4 | 10 | 2 |
| Phase 1 | 27 | 12 | 1 | 2 |
| Phase 2 | 357 | 51 | 83 | 17 |
| Phase 3 | 54 | 8 | 19 | 2 |
| Phase 4 | 9 | 2 | 1 | 1 |
| All trials | 483 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2010 to now |
| Elevar Therapeutics | Lead sponsor of trials | 2012 to now |
| Bukwang Pharmaceutical | Lead sponsor of trials | 2016 to now |
| Jiangsu ShengDiYa Medicine | Lead sponsor of trials | 2016 to now |
| Jiangsu Hansoh Pharmaceutical | Lead sponsor of trials | 2017 to now |
| Qilu Pharmaceutical | Lead sponsor of trials | 2017 to now |